Eli Lilly and Company (LLY) 76.85 $LLY Research
Post# of 273257
Posted On: 09/05/2016 5:14:44 PM
Eli Lilly and Company (LLY) 76.85 $LLY
Research and Markets - Global Insulin Delivery Systems Market 2016-2020 - Key vendors are Novo Nordisk, Sanofi, BD, Eli Lilly & Medtronic
PR Newswire Europe - Fri Sep 02, 9:11AM CDT
DUBLIN, September 2, 2016 /PRNewswire/ --
MDT: 87.32 (+0.34), LLY: 76.85 (-0.38)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 313.59 (+7.56), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Global Insulin Delivery Systems Market 2016-2020 with Novo Nordisk, Sanofi, BD, Eli Lilly & Medtronic Dominating
GlobeNewswire - Fri Sep 02, 7:33AM CDT
Research and Markets has announced the addition of the "Global Insulin Delivery Systems Market 2016-2020" report to their offering.
MDT: 87.32 (+0.34), LLY: 76.85 (-0.38)
Express Scripts' New Program to Lower Diabetes Care Costs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:00AM CDT
Express Scripts Holding Company (ESRX) has launched the Diabetes Care Value Program to lower costs for patients and provide better care.
ESRX: 72.54 (+0.32), ANIP: 59.86 (-1.56), LLY: 76.85 (-0.38)
Research and Markets - Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating the $150+ Billion Market
PR Newswire Europe - Wed Aug 31, 6:10AM CDT
DUBLIN, August 31, 2016 /PRNewswire/ --
MRK: 62.98 (+0.08), LLY: 76.85 (-0.38)
Jamere Jackson Elected to Lilly Board of Directors
PR Newswire - Wed Aug 31, 5:45AM CDT
The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Jamere Jackson as a new member, effective October 1, 2016. As a member of Lilly's board, he will serve on the Audit and Finance committees.
LLY: 76.85 (-0.38)
Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating
GlobeNewswire - Wed Aug 31, 3:16AM CDT
Research and Markets has announced the addition of the "Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment" report to their offering.
MRK: 62.98 (+0.08), LLY: 76.85 (-0.38)
Macrocure Stock Up on Merger Deal with Leap Therapeutics
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:05AM CDT
Macrocure Ltd. (MCUR) announced that it has signed a definitive merger agreement with the privately held company, Leap Therapeutics, Inc.
ANIP: 59.86 (-1.56), MCUR: 1.58 (-0.07), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 45.80 (-0.54), MRK: 62.98 (+0.08), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28)
Drug Makers Stocks under Review -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu Aug 25, 6:30AM CDT
Stock-Callers.com has initiated research reports on the following Major Drug Manufacturers in the Healthcare sector: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). On Wednesday, August 17, 2016, Brean Capital downgraded the sector to "Underweight" on technical indicators such as deteriorating relative strength, price momentum, and momentum of breadth. Learn more about these stocks by downloading their free research reports in PDF format at: http://stock-callers.com/registration
AZN: 33.31 (+0.71), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41)
Lilly to Participate in Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Aug 24, 10:00AM CDT
Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016. Jeffrey Simmons, senior vice president and president, Elanco Animal Health, will participate in a fireside chat at 10:35 a.m. Eastern Time.
LLY: 76.85 (-0.38)
Open Innovation Pioneer InnoCentive Celebrates 15 Years
PR Newswire - Wed Aug 24, 7:35AM CDT
This year, InnoCentive, the open innovation and crowdsourcing pioneer, celebrates their 15th birthday. Since launching as part of Eli Lilly in 2001, InnoCentive has gone on to apply their Challenge Driven Innovation(TM) methodology across a range of industries and disciplines. To date they have run more than 2,000 external 'Challenges', building up a problem-solving network of over 375,000 individuals and other solution providers from nearly 200 different countries in the process.
LLY: 76.85 (-0.38)
Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 7:59AM CDT
Eli Lilly (LLY) and AstraZeneca's (AZN) Alzheimer's disease treatment is currently in phase III studies.
ZTS: 51.26 (+0.15), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38)
Osteoporosis Companies Drugs (Merck, Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast 2010-2019 - Research and Markets
BusinessWire - Mon Aug 22, 5:04AM CDT
Research and Markets has announced the addition of the "Osteoporosis Companies Drugs (Merck, Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast" report to their offering.
MRK: 62.98 (+0.08), LLY: 76.85 (-0.38), NVS: 79.38 (+1.11)
Research and Markets - Global Premature Ejaculation Treatment Market CAGR Growth of 9.65% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: Pfizer, Emcure, Eli Lilly
PR Newswire Europe - Wed Aug 17, 8:10AM CDT
DUBLIN, August 17, 2016 /PRNewswire/ --
LLY: 76.85 (-0.38)
Epizyme Doses First Patient in Phase II Mesothelioma Study
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 8:25AM CDT
Epizyme (EPZM) dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma, characterized by BAP1 loss-of-function.
ADRO: 14.49 (+0.27), EPZM: 7.16 (-0.15), LLY: 76.85 (-0.38)
PrEP Biopharm Limited announces addition of Jim Cornelius and Clive Page to its Board of Directors
PR Newswire Europe - Thu Aug 11, 6:01AM CDT
PrEP Biopharm Limited, a private independent drug development company for respiratory infectious disease products, announced that Jim Cornelius, former chairman and CEO of Bristol-Myers Squibb, and Clive Page, PhD, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology at King's College London, have joined the company's Board of Directors. They bring expansive strategic, operational and scientific experience to the Board.
DTV: 93.55 (+1.36), LLY: 76.85 (-0.38), BMY: 56.35 (-0.41)
Elanco Launches New Video Series Illustrating the Powerful Bond Between Service Dogs, Owners
PR Newswire - Thu Aug 11, 6:00AM CDT
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and the makers of Trifexis® (spinosad + milbemycin oxime), today launched its Celebrate the Bond video series that lets viewers share the experience of two individuals embarking on life-changing relationships.
LLY: 76.85 (-0.38)
Research and Markets - Global Insulin Delivery Systems Market 2016-2020 - Key vendors are Novo Nordisk, Sanofi, BD, Eli Lilly & Medtronic
PR Newswire Europe - Fri Sep 02, 9:11AM CDT
DUBLIN, September 2, 2016 /PRNewswire/ --
MDT: 87.32 (+0.34), LLY: 76.85 (-0.38)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 313.59 (+7.56), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Global Insulin Delivery Systems Market 2016-2020 with Novo Nordisk, Sanofi, BD, Eli Lilly & Medtronic Dominating
GlobeNewswire - Fri Sep 02, 7:33AM CDT
Research and Markets has announced the addition of the "Global Insulin Delivery Systems Market 2016-2020" report to their offering.
MDT: 87.32 (+0.34), LLY: 76.85 (-0.38)
Express Scripts' New Program to Lower Diabetes Care Costs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:00AM CDT
Express Scripts Holding Company (ESRX) has launched the Diabetes Care Value Program to lower costs for patients and provide better care.
ESRX: 72.54 (+0.32), ANIP: 59.86 (-1.56), LLY: 76.85 (-0.38)
Research and Markets - Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating the $150+ Billion Market
PR Newswire Europe - Wed Aug 31, 6:10AM CDT
DUBLIN, August 31, 2016 /PRNewswire/ --
MRK: 62.98 (+0.08), LLY: 76.85 (-0.38)
Jamere Jackson Elected to Lilly Board of Directors
PR Newswire - Wed Aug 31, 5:45AM CDT
The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Jamere Jackson as a new member, effective October 1, 2016. As a member of Lilly's board, he will serve on the Audit and Finance committees.
LLY: 76.85 (-0.38)
Global Billion Diabetes and Obesity Drugs Market 2016-2022 with Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca & Takeda Dominating
GlobeNewswire - Wed Aug 31, 3:16AM CDT
Research and Markets has announced the addition of the "Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment" report to their offering.
MRK: 62.98 (+0.08), LLY: 76.85 (-0.38)
Macrocure Stock Up on Merger Deal with Leap Therapeutics
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:05AM CDT
Macrocure Ltd. (MCUR) announced that it has signed a definitive merger agreement with the privately held company, Leap Therapeutics, Inc.
ANIP: 59.86 (-1.56), MCUR: 1.58 (-0.07), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Sponsor and CRO Finalists Announced for Annual Society for Clinical Research Sites' Eagle Award
PR Newswire - Thu Aug 25, 9:00AM CDT
The Society for Clinical Research Sites announces today the finalists for the 2016 SCRS Eagle Award(TM). The finalists were selected from nominations provided by SCRS members. Qualifying nominees were in the 75th percentile or higher of the total nominations submitted for the Eagle Award. Voting is now open to all clinical research site professionals, regardless of their membership with SCRS, and closes September 21, 2016. Go to this website to vote.
NVO: 45.80 (-0.54), MRK: 62.98 (+0.08), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28)
Drug Makers Stocks under Review -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Thu Aug 25, 6:30AM CDT
Stock-Callers.com has initiated research reports on the following Major Drug Manufacturers in the Healthcare sector: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). On Wednesday, August 17, 2016, Brean Capital downgraded the sector to "Underweight" on technical indicators such as deteriorating relative strength, price momentum, and momentum of breadth. Learn more about these stocks by downloading their free research reports in PDF format at: http://stock-callers.com/registration
AZN: 33.31 (+0.71), LLY: 76.85 (-0.38), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41)
Lilly to Participate in Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Aug 24, 10:00AM CDT
Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016. Jeffrey Simmons, senior vice president and president, Elanco Animal Health, will participate in a fireside chat at 10:35 a.m. Eastern Time.
LLY: 76.85 (-0.38)
Open Innovation Pioneer InnoCentive Celebrates 15 Years
PR Newswire - Wed Aug 24, 7:35AM CDT
This year, InnoCentive, the open innovation and crowdsourcing pioneer, celebrates their 15th birthday. Since launching as part of Eli Lilly in 2001, InnoCentive has gone on to apply their Challenge Driven Innovation(TM) methodology across a range of industries and disciplines. To date they have run more than 2,000 external 'Challenges', building up a problem-solving network of over 375,000 individuals and other solution providers from nearly 200 different countries in the process.
LLY: 76.85 (-0.38)
Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 7:59AM CDT
Eli Lilly (LLY) and AstraZeneca's (AZN) Alzheimer's disease treatment is currently in phase III studies.
ZTS: 51.26 (+0.15), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38)
Osteoporosis Companies Drugs (Merck, Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast 2010-2019 - Research and Markets
BusinessWire - Mon Aug 22, 5:04AM CDT
Research and Markets has announced the addition of the "Osteoporosis Companies Drugs (Merck, Sanofi, Novartis, Eli Lilly and Amgen) Sales & Forecast" report to their offering.
MRK: 62.98 (+0.08), LLY: 76.85 (-0.38), NVS: 79.38 (+1.11)
Research and Markets - Global Premature Ejaculation Treatment Market CAGR Growth of 9.65% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: Pfizer, Emcure, Eli Lilly
PR Newswire Europe - Wed Aug 17, 8:10AM CDT
DUBLIN, August 17, 2016 /PRNewswire/ --
LLY: 76.85 (-0.38)
Epizyme Doses First Patient in Phase II Mesothelioma Study
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 8:25AM CDT
Epizyme (EPZM) dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma, characterized by BAP1 loss-of-function.
ADRO: 14.49 (+0.27), EPZM: 7.16 (-0.15), LLY: 76.85 (-0.38)
PrEP Biopharm Limited announces addition of Jim Cornelius and Clive Page to its Board of Directors
PR Newswire Europe - Thu Aug 11, 6:01AM CDT
PrEP Biopharm Limited, a private independent drug development company for respiratory infectious disease products, announced that Jim Cornelius, former chairman and CEO of Bristol-Myers Squibb, and Clive Page, PhD, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology at King's College London, have joined the company's Board of Directors. They bring expansive strategic, operational and scientific experience to the Board.
DTV: 93.55 (+1.36), LLY: 76.85 (-0.38), BMY: 56.35 (-0.41)
Elanco Launches New Video Series Illustrating the Powerful Bond Between Service Dogs, Owners
PR Newswire - Thu Aug 11, 6:00AM CDT
Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and the makers of Trifexis® (spinosad + milbemycin oxime), today launched its Celebrate the Bond video series that lets viewers share the experience of two individuals embarking on life-changing relationships.
LLY: 76.85 (-0.38)
(0)
(0)Scroll down for more posts ▼